Zai Lab 2026 ESMO Investor Call - ZAI LAB LTD

Explicit Guidance:

• No explicit numerical financial guidance (revenue, earnings, margins, capex, etc.) provided in this transcript.
• Expected timing for a potential USBLA (Biologics License Application) submission: next year.
• Multiple important data readouts for key programs expected over the next 12 to 18 months.

Business-Segment Outlook:

• SOZI (DLL-3 ADC):
  • Entering a pivotal period with three registrational trials expected to be underway by the end of the year: (1) ongoing second-line Small Cell Lung Cancer (SCLC) trial (DELEVATE), (2) second-line extrapulmonary NEC, and (3) first-line SCLC trial.
  • Goal to initiate the global Phase III first-line SCLC study by the end of the year (specifically by end of current year).
  • Atezolizumab combination (doublet) showing 81.4% objective response rate (ORR) in first-line vs. 60-68% for standard chemo-immunotherapy; 81.9% 6-month progression-free survival (PFS) vs. ~30% for standard care.
  • Triplet (doublet + carboplatin) showing 92.3% ORR but with substantially higher toxicity; decision made to pursue doublet for Phase III to prioritize tolerability and quality of life.
  • Vision to replace chemotherapy with SOZI as the backbone in frontline treatment for all patients, removing attrition between induction and maintenance.
• ZL-15L3 (Immunology):
  • First clinical data readout for long-acting IL-13/IL-31 receptor alpha expected next month.
  • Potential differentiation in atopic dermatitis and other inflammatory diseases via dual pathway inhibition and extended dosing intervals.
• Pipeline Expansion:
  • Exploring opportunities in immediate-stage SCLC, large cell neuroendocrine carcinoma, and brain tumors where DLL-3 is expressed.

Market and Competitive Outlook:

• Standard of Care Evolution: Current standard involves platinum-etoposide + immunotherapy followed by durvalumab or tarlatamab maintenance; management sees an opportunity to replace chemotherapy entirely with ADCs in the frontline setting.
• Competitive Landscape: SCLC is increasingly competitive; SOZI is positioned as an "agent of choice" due to high response rates, robust intracranial activity (60%+ in prior analyses), and favorable safety profile compared to other ADCs (lower ILD rates).
• Combination Potential: Strong complementarity anticipated with T-cell engagers (specifically Amgen's tarlatamab) and checkpoint inhibitors (atezolizumab), potentially creating deeper and more durable disease control than monotherapy or chemo-backbones.
• Treatment Paradigm Shift: Expectation to move from "induction + maintenance" models to "continuous frontline treatment" using ADCs to treat patients earlier and maintain response longer.

Macro / Industry Outlook:

• Regulatory: Early review of data conducted with regulators for the first-line study design; "green light" received to proceed with the Phase III trial.
• Clinical Trends: Recognition that intracranial activity is critical (80% of SCLC patients develop brain mets); standard care progression is often rapid (<5 months), necessitating faster-acting, more durable therapies.
• Global Development: Execution focus on generating data to realize dose's full potential across global regions, noting no observed efficacy/safety differences between Asian and non-Asian cohorts.

Strategic Initiatives:

• Partnerships:
  • Ongoing collaboration with Vi (likely referring to Vaxcyte or similar partner context, though transcript says "VI") and Amgen to develop SOZI as a standard of care backbone in combination with T-cell engagers and immunotherapy.
  • Focus on realizing the potential of combinations as the standard of care evolves.
• Clinical Trials:
  • Phase III First-Line SCLC: Aiming to start study by end of year; doublet (SOZI + atezolizumab) vs. chemo + IO; patients with brain metastases allowed.
  • Phase II/III Extrapulmonary NEC: Fully enrolled for potential registrational study.
  • Second-Line SCLC: Ongoing accrual with plans for data analysis and filing next year.
• Product Strategy:
  • Moving from monotherapy focus in second-line to combination backbone strategies in first-line to maximize tolerability and continuous treatment duration.
  • Willing to reserve chemotherapy for later lines if SOZI-based regimens prove superior in frontline safety/efficacy.

Risks and Headwinds to Outlook:

• Toxicity Profiles: Triplets (SOZI + Atezo + Carboplatin) showed substantially more toxicity (hematological) and treatment interruptions compared to doublets; this necessitates the shift to doublet for Phase III to ensure tolerability.
• Data Maturity: Early safety and efficacy data are still maturing; longer follow-up remains critical to confirm consistency with monotherapy safety profiles (specifically regarding Interstitial Lung Disease/ILD).
• Competitive Uncertainty: Final positioning and combination strategies (e.g., with T-cell engagers) depend on ongoing partner study results; no guarantee on T-cell engager activity in specific subgroups like brain mets.
• Operational Execution: Standing up the Phase III first-line study requires significant operational work; timelines depend on successful enrollment.
• Intracranial Data: Specific intracranial response data for the first-line doublet has not yet been independently reviewed; assumed to be positive based on second-line data but requires confirmation.

Management Tone on the Future:

• Confidence Level: High confidence in SOZI's potential ("strong clinical rationale," "very encouraging," "best in class tolerability").
• Strategic Shift: Decisive pivot toward replacing chemotherapy in the frontline setting based on the superior efficacy-to-tolerability profile of the doublet.
• Differentiation: Emphasizes SOZI's safety profile as a key differentiator enabling broader combination use (monotherapy and backbone) compared to the "narrow therapeutic window" of other ADCs.
• Vision: Confident that the future of SCLC treatment will be built on "new combination regimens" where SOZI serves as the backbone, potentially eliminating the need for chemotherapy in the first line.